Search research articles
Contact Us
Filters
Showing results (101-110 of 176) with videos related to
Page
of 18
Sort By:
Investigational New Drugs
|
October 19, 2018
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer
Laura W Goff, Nilofer S Azad, Stacey Stein, et al.
The Journal of Urology
|
November 1, 2022
A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer
Irene Tsung, Edward Green, Phillip Palmbos, et al.
The Oncologist
|
April 11, 2025
A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC
Andrew W Hahn, Nabil Adra, Ulka Vaishampayan, et al.
Human Pathology
|
December 13, 2022
Deciphering intratumor heterogeneity in clear cell renal cell carcinoma utilizing clinicopathologic and molecular platforms
Erica Vormittag-Nocito, Rahul Mannan, Xiaoming Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2007
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial
Maha H A Hussain, Gary R MacVicar, Daniel P Petrylak, et al.
American Journal of Clinical Pathology
|
July 27, 2023
Lessons from 801 clinical TFE3/TFEB fluorescence in situ hybridization assays performed on renal cell carcinoma suspicious for MiTF family aberrations
Xiao-Ming Wang, Lina Shao, Hong Xiao, et al.
Cancer
|
May 21, 2016
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies
Rana R McKay, Guillermo De Velasco, Lillian Werner, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 7, 2021
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
Jean-François Martini, Elizabeth R Plimack, Toni K Choueiri, et al.
The Oncologist
|
June 8, 2019
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
M Dror Michaelson, Shilpa Gupta, Neeraj Agarwal, et al.
Page
of 18
Search research articles
Search
Showing results (101-110 of 176) with videos related to
Sort By:
Page
of 18
Investigational New Drugs
|
October 19, 2018
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer
Laura W Goff, Nilofer S Azad, Stacey Stein, et al.
The Journal of Urology
|
November 1, 2022
A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer
Irene Tsung, Edward Green, Phillip Palmbos, et al.
The Oncologist
|
April 11, 2025
A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC
Andrew W Hahn, Nabil Adra, Ulka Vaishampayan, et al.
Human Pathology
|
December 13, 2022
Deciphering intratumor heterogeneity in clear cell renal cell carcinoma utilizing clinicopathologic and molecular platforms
Erica Vormittag-Nocito, Rahul Mannan, Xiaoming Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2007
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial
Maha H A Hussain, Gary R MacVicar, Daniel P Petrylak, et al.
American Journal of Clinical Pathology
|
July 27, 2023
Lessons from 801 clinical TFE3/TFEB fluorescence in situ hybridization assays performed on renal cell carcinoma suspicious for MiTF family aberrations
Xiao-Ming Wang, Lina Shao, Hong Xiao, et al.
Cancer
|
May 21, 2016
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies
Rana R McKay, Guillermo De Velasco, Lillian Werner, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 7, 2021
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
Jean-François Martini, Elizabeth R Plimack, Toni K Choueiri, et al.
The Oncologist
|
June 8, 2019
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
M Dror Michaelson, Shilpa Gupta, Neeraj Agarwal, et al.
Page
of 18